Escitalopram Oxalate Tablet, Film Coated
Product Images NDC 69097-849

This is a description of a prescription drug named Escitalopram, which comes as tablets. The drug contains Escitalopram oxalate and is manufactured by InvaGen Pharmaceuticals, Inc., which is a subsidiary of Cipla L. It is advised to keep this medicine in a tight container away from children. The suggested storage temperature is listed in the USP Controlled Room Temperature. The package insert should be consulted for the recommended dosage. The medication guide should be provided separately to each patient. The lot number and related information are included as well.*

This is a prescription drug containing Escitalopram. It comes in tablet form and each tablet contains 20 mg of escitalopram. The usual dosage is mentioned in the package insert. The medication guide should be distributed to each patient by the pharmacist. It is manufactured by InvaGen Pharmaceuticals, Inc., a subsidiary of Cipla Lic. It should be stored in a tight container at a controlled room temperature of 20°-25°C (68°77°F) and kept out of the reach of children. The Lot No. is 210208.*

This is a medication distributed under the NDC code 69097-84705, named Escitalopram. It comes in tablet form and is available by prescription only. The package comes with 90 tablets, and the pharmacist is responsible for dispensing the medication guide to each patient. The medication should be kept out of the reach of children, and it should be stored in a tightly sealed container per USP guidelines at a temperature range of 20°C-25°C (68°F-77°F). The package insert should be consulted for complete prescribing information and dosage recommendations. The medication is manufactured by Cipla USA Inc, and this product is a subsidiary of Cipla Ltd.*

This text appears to be a table presenting the drug-placebo difference in the number of cases of suicidality per 1000 patients treated within different age ranges. The table shows an increase in the number of cases of suicidality among patients under 18 years old for the drug compared to placebo. However, for patients aged over 18, there is a decrease in the number of cases of suicidality compared to placebo. No further information is provided in the text.*

This is a tabular summary of treatment-emergent adverse reactions observed with a frequency greater than 2% and greater than placebo for Major Depressive Disorder. The table compares the incidence of adverse reactions between Escitalopram and Placebo which includes the number of patients and percentage. The observed adverse reactions are categorized by system disorders such as Autonomic Nervous System Disorders, Central & Peripheral Nervous System Disorders, Gastrointestinal Disorders, General, Psychiatric Disorders, Respiratory System Disorders, and Urogenital. The table also notes the Denominator used for males only and females only for some adverse reactions.*

This is a table showing the treatment-emergent adverse reactions observed in patients with Generalized Anxiety Disorder who were given escitalopram compared to placebo. The table denotes the percentage of patients experiencing different adverse reactions, including dry mouth, sweating, increased nausea, diarrhea, dizziness, insomia, and other symptoms. The table also includes the denominator used for males and females.*

The text shows incidence rates of common adverse reactions in patients with Major Depressive Disorder who were administered Placebo, 10mg/day, and 20mg/day of Escitalopram. The reactions include Insomnia, Diarrhea, Dry Mouth, Somnolence, Dizziness, Sweating Increased, Constipation, Faigue, and Indigestion, and are shown as percentages.*

The text describes a table showing the incidence of sexual side effects in clinical trials comparing a drug called Escitalopram to a placebo. The table shows the percentage of patients experiencing adverse events such as ejaculation disorder, ejaculatory delay, decreased libido, impotence, and anorgasmia in both male and female patients. The data seems to be divided by location, specifically the incidence in Wales.*